Prostate Cancer:

Sirexatamab (DKN-01) in prostate cancer

High expression of DKK1 has been linked to an immune-suppressive tumor microenvironment in prostate cancer and poor outcomes. Preclinical data indicates that sirexatamab (DKN-01) has activity in tumor models that express DKK1.

Posters for the prostate cancer indication

• A Phase 1/2 Multicenter Investigator-Initiated Trial of DKN-01 as Monotherapy or in Combination with Docetaxel for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) – (Poster)
• A Phase 1/2 Multicenter Investigator-Initiated Trial of DKN-01 as Monotherapy or in Combination with Docetaxel for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) – (Slides)
• DKK1 defines a non-neuroendocrine subtype of mCRPC with low AR and low PSA expression